Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Bought by Kestra Private Wealth Services LLC

Posted by Defense World Staff on Apr 21st, 2023

Kestra Private Wealth Services LLC boosted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) by 23.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,585 shares of the company’s stock after buying an additional 5,168 shares during the period. Kestra Private Wealth Services LLC’s holdings in Teva Pharmaceutical Industries were worth $252,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in TEVA. Bank of New York Mellon Corp grew its stake in Teva Pharmaceutical Industries by 1.6% during the 1st quarter. Bank of New York Mellon Corp now owns 1,875,394 shares of the company’s stock valued at $17,609,000 after purchasing an additional 28,920 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Teva Pharmaceutical Industries by 12.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 119,076 shares of the company’s stock valued at $1,118,000 after purchasing an additional 13,069 shares during the last quarter. MetLife Investment Management LLC grew its stake in Teva Pharmaceutical Industries by 4.7% during the 1st quarter. MetLife Investment Management LLC now owns 95,953 shares of the company’s stock valued at $901,000 after purchasing an additional 4,300 shares during the last quarter. BlackRock Inc. grew its stake in Teva Pharmaceutical Industries by 3.7% during the 1st quarter. BlackRock Inc. now owns 41,648,716 shares of the company’s stock valued at $391,081,000 after purchasing an additional 1,494,814 shares during the last quarter. Finally, Great West Life Assurance Co. Can grew its stake in Teva Pharmaceutical Industries by 4.0% during the 1st quarter. Great West Life Assurance Co. Can now owns 420,533 shares of the company’s stock valued at $4,137,000 after purchasing an additional 16,134 shares during the last quarter. 50.39% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Sven Dethlefs sold 59,655 shares of the stock in a transaction that occurred on Tuesday, February 28th. The stock was sold at an average price of $9.89, for a total transaction of $589,987.95. Following the transaction, the executive vice president now owns 165,381 shares in the company, valued at $1,635,618.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Teva Pharmaceutical Industries news, VP David Matthew Stark sold 16,491 shares of the stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $9.93, for a total transaction of $163,755.63. Following the completion of the transaction, the vice president now owns 52,449 shares of the company’s stock, valued at $520,818.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sven Dethlefs sold 59,655 shares of the stock in a transaction that occurred on Tuesday, February 28th. The shares were sold at an average price of $9.89, for a total value of $589,987.95. Following the transaction, the executive vice president now directly owns 165,381 shares of the company’s stock, valued at approximately $1,635,618.09. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 158,884 shares of company stock worth $1,572,797. 0.82% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Trading Down 1.6 %

Shares of TEVA opened at $8.35 on Friday. The stock’s 50-day moving average price is $9.29 and its 200-day moving average price is $9.28. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.72 and a current ratio of 1.05. Teva Pharmaceutical Industries Limited has a 52 week low of $6.78 and a 52 week high of $11.44.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) last issued its quarterly earnings results on Wednesday, February 8th. The company reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.04. The company had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.90 billion. Teva Pharmaceutical Industries had a positive return on equity of 28.06% and a negative net margin of 15.76%. As a group, equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.3 EPS for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on TEVA shares. Jefferies Financial Group downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating and boosted their price target for the company from $10.00 to $12.00 in a research note on Thursday, January 19th. Barclays upped their target price on Teva Pharmaceutical Industries from $13.00 to $14.00 and gave the stock an “overweight” rating in a research note on Thursday, February 9th. Finally, StockNews.com assumed coverage on Teva Pharmaceutical Industries in a research note on Thursday, March 16th. They issued a “buy” rating on the stock. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $10.75.

Teva Pharmaceutical Industries Company Profile

(Get Rating)

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.